Akero Therapeutics, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US00973Y1082

USD

54.63

0.14 (0.26%)

Dec 04

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Amicus Therapeutics, Inc.

Madrigal Pharmaceuticals, Inc.

ACADIA Pharmaceuticals, Inc.

Prestige Consumer Healthcare, Inc.

Corcept Therapeutics, Inc.

Insmed, Inc.

Cytokinetics, Inc.

Cerevel Therapeutics Holdings, Inc.

Akero Therapeutics, Inc.

MoonLake Immunotherapeutics

Bausch Health Cos., Inc.

Why is Akero Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Akero Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Akero Therapeutics, Inc.

77.66%

1.22

112.18%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-226.51%

EBIT to Interest (avg)

-82.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.60

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.99

EV to EBIT

-12.00

EV to EBITDA

-12.00

EV to Capital Employed

8.48

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-70.64%

ROE (Latest)

-24.86%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -141.23 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-10What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -253.42 MM

DEBT-EQUITY RATIO (HY)

Highest at -68.74 %

PRE-TAX PROFIT(Q)

Fallen at -25.93%

NET PROFIT(Q)

Fallen at -25.93%

Here's what is working for Akero Therapeutics, Inc.

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Akero Therapeutics, Inc.

Operating Cash Flow

Lowest at USD -253.42 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit

Fallen at -25.93%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Fallen at -25.93%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -68.74 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio